Japan’s MHLW Approves MPS VI Drug Naglazyme
This article was originally published in PharmAsia News
Executive Summary
Osaka-based AnGes MG announced that Naglazyme intravenousmucopolysaccharidosis VI drug was approved during the first session of Japan's Ministry of Health, Labor and Welfare Drug Review Board. MPS VI is a genetic disorder caused by the deficiency of arylsulfatase B, whereby the normal breakdown of dermatan sulfate and chondroitin sulfate is blocked and accumulates in the body. Naglazyme isa replacement therapy that infuses exogenous enzymes. It was designated an orphan drug by the MHLW in June 2008. AnGes MG signed a deal with manufacturer BioMarin Pharmaceutical and gained exclusive rights to market and distribute Naglazyme in Japan. (Click for more-Japanese language
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.